Use of certain drugs for treating nerve root injury
AssigneeA+ Science AB (publ)
InventorsKjell Olmarker, Bjorn Rydevik
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-α comprising an effective amount of a TNF-α inhibitor, as well as a method for treatment of such disorders, and the use of TNF-α inhibitors in the preparation of pharmaceutical compositions for such treatment.
Claims2
A method of treating a nerve disorder in a mammal in need of such treatment comprising the step of administering a TNF-α inhibitor selected from the group consisting of:
- (a) metalloproteinase inhibitors excluding methylprenisolone, (b) quinolones, (c) corticosteroids, (d) thalidomide, (e) lazaroides, (f) pentoxyphyllines, (g) hydroxamic acid derivatives, (h) carbocyclic acids, (i) napthopyrans, (j) amrinone, (k) pimobendan, (1) vesnarinone, (m) phosphodiesterase III inhibitors, (n) lactoferrin and lactoferrin derived analogs, (o) melatonin, and bases or addition salts thereof, for the treatment of nerve disorders in said mammal in need of such treatment wherein said nerve disorder is caused by the liberation of TNF-α and compounds triggered by the liberation of or presence of TNF-α by inhibiting TNF-α.
A pharmaceutical composition for the treatment of a nerve disorder in a mammal in need of such treatment comprising a pharmaceutically effective amount of a TNF-α inhibitor selected from the group consisting of:
- (a) metalloproteinase inhibitors excluding methylprenisolone, (b) quinolones, (c) corticosteroids, (d) thalidomide, (e) lazaroides, (f) pentoxyphyllines, (g) hydroxamic acid derivatives, (h) carbocyclic acids, (i) napthopyrans, (j) amrinone, (k) pimobendan, (l) vesnarinone, (m) phosphodiesterase III inhibitors, (n) lactoferrin and lactoferrin derived analogs, (o) melatonin, and bases or addition salts thereof, and a pharmaceutically acceptable carrier for the treatment of nerve disorders in said mammal in need of such treatment wherein said nerve disorder is caused by the liberation of TNF-α and compounds triggered by the liberation of or presence of TNF-α by inhibiting TNF-α.
Dependencies are inferred from the claim text.